# Abbott Laboratories (ABT)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ABT/primer

## Business Model

---
ticker: ABT
step: 01
generated: 2026-05-12
source: quick-research
---

### Abbott Laboratories (ABT) — Business Overview

#### Business Description
Abbott Laboratories is a diversified healthcare company operating across four segments: Medical Devices (45% of revenue), Nutrition (22%), Diagnostics (20%), and Established Pharmaceuticals (13%). The portfolio anchored by FreeStyle Libre (#1 global continuous glucose monitor — $7B+ run rate growing 20%+) and structural heart franchise (MitraClip, TriClip, Amplatzer Amulet). The March 2026 close of the $20B+ Exact Sciences acquisition adds high-growth cancer diagnostics. Robert Ford is CEO.

#### Revenue Model
- **Medical Devices (~45% of revenue):** Diabetes (FreeStyle Libre CGM + Lingo consumer biosensor), Cardiovascular (Coronary, Structural Heart, Heart Failure, Vascular), Neuromodulation, Rhythm Management (AVEIR leadless pacemakers, Volt PFA)
- **Nutrition (~22%):** Pediatric (Similac, PediaSure), Adult (Ensure, Glucerna), International nutrition
- **Diagnostics (~20%):** Core Lab (Alinity), Molecular (m2000, Alinity m), Rapid Diagnostics, Point of Care (post-Exact Sciences: cancer screening)
- **Established Pharmaceuticals (EPD, ~13%):** Branded generics primarily in emerging markets (India, Latin America, China, Russia, etc.)

#### Products & Services

##### Medical Devices
- **FreeStyle Libre family:** Libre 2 Plus, Libre 3 Plus, Libre 4 (under development), Lingo consumer wellness biosensor — #1 CGM globally
- **Cardiovascular:** XIENCE coronary stents, MitraClip + TriClip (transcatheter heart valves), Amplatzer Amulet (LAA closure), Navitor, HeartMate (heart failure)
- **Rhythm Management:** AVEIR leadless pacemakers (single + dual-chamber), Volt PFA (pulsed field ablation, FDA approved Dec 22, 2025)
- **Vascular:** XIENCE PRO, Esprit BTK
- **Neuromodulation:** Spinal cord stim, deep brain stim, dorsal root ganglion

##### Diagnostics
- **Alinity:** Integrated lab platform
- **m2000 / Alinity m:** Molecular (PCR)
- **Rapid Diagnostics:** BinaxNOW, ID Now
- **Exact Sciences (March 2026):** Cologuard (colorectal cancer screening), Oncotype DX

##### Nutrition
- **Pediatric:** Similac infant formula, PediaSure, Pedialyte
- **Adult:** Ensure, Glucerna, ZonePerfect
- **International nutrition (high growth in EM)**

##### Established Pharmaceuticals
- Branded generics in ~15 emerging markets
- Cardiology, hepatology, gastroenterology, women's health franchises

#### Customer Base & Go-to-Market
- **Patients:** Billions globally — Libre alone has ~6M users, Cologuard 4M+ tests annually
- **Physicians + Hospitals:** Cardiologists, electrophysiologists, endocrinologists, OB-GYN, primary care
- **Pharmacies + retailers:** Nutrition products through grocery + drug + Amazon
- **Public sector:** WIC + global infant nutrition programs
- **Geographic mix:** ~40% International, ~60% US

#### Competitive Position
Abbott has multiple #1 or #2 positions in major franchises: #1 in CGM (Libre vs Dexcom G7), #1 in heart valve replacement via MitraClip, #1 nutritional products company globally. Moats: (1) Libre cost-efficient CGM strategy (lower price + broader access vs Dexcom premium), (2) MitraClip first-mover advantage in TEER market, (3) AVEIR dual-chamber leadless pacemaker first to market, (4) Exact Sciences Cologuard franchise dominant in colorectal screening. Faces (1) Dexcom in CGM (especially G8/Stelo), (2) Boston Scientific in PFA + electrophysiology, (3) Medtronic broadly across devices.

#### Key Facts
- Founded: 1888 (Wallace C. Abbott)
- Headquarters: Abbott Park, IL
- Employees: ~115,000
- Exchange: NYSE
- Sector / Industry: Health Care / Medical Devices + Diagnostics + Nutrition
- Market Cap: ~$215B (May 2026)
- CEO: Robert B. Ford (since 2020)
- Dividend: $2.36 annual ($0.59 quarterly)
- 52 consecutive years of dividend growth (Dividend King)
- Major M&A: Exact Sciences $20B+ (closed March 2026); legacy: AbbVie spin-off 2013, St. Jude Medical $25B 2017

## Financial Snapshot

---
ticker: ABT
step: 04
generated: 2026-05-12
source: quick-research
---

### Abbott Laboratories (ABT) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $40.1B | $42.0B | $44.5B | +6% |
| Organic Sales Growth | flat | +7.1% | +8% | |
| Gross Margin | 55.5% | 56.0% | 56.5% | +50bps |
| Adj. Operating Margin | 20.2% | 22.6% | 23.5% | +90bps |
| Adj. Net Income | $7.6B | $8.1B | $9.0B | +11% |
| Adj. EPS | $4.44 | $4.67 | $5.18 | +11% |
| Free Cash Flow | $6.4B | $6.5B | $7.2B | +11% |

#### Segment Revenue (FY2025)

| Segment | Revenue | YoY Growth |
|---------|---------|-----------|
| Medical Devices | $20.2B | +9% (Diabetes +18%, CV +11%) |
| Diagnostics | $9.0B | flat (COVID drag) |
| Nutrition | $8.5B | -2% (volume weakness) |
| Established Pharmaceuticals | $5.7B | +9% |

#### Q1 2026 Highlights

| Metric | Q1 2026 |
|--------|---------|
| Medical Devices Growth | +8.5% |
| Diabetes Care (Libre) | $2.08B (annualizes to $8.3B) |
| Continuous Glucose Monitoring | $2B+ (+7.5%) — affected by recall |
| Rhythm Management | +17% (AVEIR) |
| Diagnostics | +3% Core Lab |
| Nutrition | Recovering from -8.9% in Q4 2025 |

#### Key Product Metrics

| Metric | Value |
|--------|-------|
| FreeStyle Libre 2025 revenue | ~$7B |
| 2028 Libre target | $10B (~10% annual growth required) |
| Lingo consumer biosensor | Launched 2024 |
| Volt PFA approval | December 22, 2025 (FDA) |
| Exact Sciences incremental revenue 2026 | ~$3B |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$8.5B |
| Capital Expenditures | ~$1.5B |
| Free Cash Flow | ~$7.2B |
| Cash & Equivalents | ~$8B |
| Total Debt | ~$15B pre-Exact Sciences; ~$35B post-Exact Sciences (+$20B for acquisition) |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~24x | EV/EBITDA: ~17x | Dividend Yield: ~2.0%
- ROIC: ~14% (will dip on Exact Sciences integration before accretion)
- FCF Margin: ~16%
- Net Debt/EBITDA: ~3x post-Exact Sciences (elevated near-term)

#### Growth Profile
FY26 sales outlook: 6.5-7.5% comparable growth. Medical Devices is the primary growth engine (especially Libre + Volt PFA + AVEIR). Q1 2026 saw Libre annualizing to $8.3B run rate. Exact Sciences ($3B incremental revenue 2026, growing high-teens) adds to Diagnostics. Bear-case overhang: FreeStyle Libre 3/3 Plus recall (3M units, FDA Class I, 860 serious injuries + 7 deaths) plus nutrition softness.

#### Forward Estimates
- **FY2026E Revenue:** ~$50B (incl. Exact Sciences full year)
- **FY2026E Adj EPS:** $5.05-5.25 (mgmt guide; +6-8%)
- **FY2027E EPS:** ~$5.85 (+12-15%)
- **FY2028E Libre revenue target:** $10B+ (vs $7B in 2025)

#### Capital Return
- Dividend $2.36 annual (~$4B paid)
- 52 consecutive years of dividend growth (Dividend King)
- Buybacks: ~$2-3B annual run rate, moderated post-Exact Sciences debt paydown priority
- Total return: ~3-4% combined yield + 10%+ EPS growth

## Recent Catalysts

---
ticker: ABT
step: 12
generated: 2026-05-12
source: quick-research
---

### Abbott Laboratories (ABT) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **FreeStyle Libre on track to $10B by 2028** — Q1 2026 Diabetes Care revenue annualized to $8.3B. Management's 2028 target of $10B Libre revenue requires only ~10% annual growth from here — below the 13.8% segment growth just posted. Lingo consumer biosensor extends Libre franchise into wellness/fitness market (not just diagnosed diabetics). New Libre 4 generation in development could re-accelerate growth.

2. **Volt PFA + AVEIR drive Cardiovascular acceleration** — December 22, 2025 FDA approval of Volt pulsed field ablation puts Abbott in fastest-growing atrial fibrillation treatment category. PFA expected to take most of the $6B US cardiac ablation market from older RF approaches by 2028. AVEIR dual-chamber leadless pacemaker drove Rhythm Management +17% in Q1 2026. Combined, these can offset slower segments.

3. **Exact Sciences acquisition adds $3B+ growing high-teens** — March 2026 close of $20B+ Exact Sciences deal adds Cologuard (colorectal cancer screening) franchise — the dominant player in colorectal screening with 80%+ market share. $3B incremental revenue 2026, growing high teens. Creates a $12B+ diagnostics platform.

4. **52-year Dividend King + recovery setup post 17% YTD decline** — Stock down ~17% YTD on Libre recall + Exact Sciences debt funding + nutrition weakness. 15 of 17 analysts rate Buy/Strong Buy; consensus 12-month target $134.29 (~40% upside). 52 consecutive dividend increases. Combination of catalysts (recall resolution, Volt PFA ramp, Exact Sciences integration) creates a multi-year compounding setup.

#### Bear Case Risks

1. **FreeStyle Libre 3/3 Plus recall — FDA Class I, 7 deaths reported** — FDA linked 860 serious injuries + 7 deaths to faulty glucose readings from certain Libre 3 / Libre 3 Plus sensors. Recall affected ~3 million units. Bear case: slower remediation, ongoing class action litigation, regulatory scrutiny could materially impact Libre growth + brand. Diabetes Care growth slowed to 7.5% in Q1 2026 (from ~20%+ pace prior to recall).

2. **Exact Sciences integration risk + $20B new debt** — $20B in new debt to fund Exact Sciences raises interest costs and integration risk. Deal not accretive until 2028. Net debt/EBITDA jumps to ~3x — elevated for Abbott. Integration of large standalone company has historical mixed results (St. Jude Medical 2017 integration was bumpy initially).

3. **Nutrition segment chronic weakness** — Nutrition revenue -8.9% in Q4 2025; -2% full year. Volume weakness + pricing actions. The infant formula crisis (Sturgis, MI plant 2022) still casts a shadow. Nutrition has historically been a stable margin contributor; persistent weakness offsets Medical Devices strength.

4. **CGM competitive + reimbursement pressure** — Dexcom G7 / G8 + Stelo over-the-counter CGM competing with Libre. US competitive bidding for CGMs (proposed in Medicare) could compress Libre pricing. Outside US, single-payer healthcare systems negotiating aggressively.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Libre recall resolution; Exact Sciences integration milestones; Volt PFA early commercial trajectory
- **FDA Libre 4 submission/approval** — Next-gen CGM platform
- **Volt PFA commercial ramp** — Critical for Cardiovascular acceleration narrative
- **Annual investor day** — Multi-year algorithm update
- **Exact Sciences accretion milestones** — Target 2028 EPS accretion

#### Analyst Sentiment

Sell-side consensus is **Buy / Strong Buy** — 15 of 17 analysts rate Buy/Strong Buy with zero Sell ratings. Average price targets cluster at $130-140 vs. recent ~$120 (post 17% YTD decline) — ~10-20% upside. Bulls cite Libre trajectory to $10B, Volt PFA + AVEIR catalysts, Exact Sciences platform, and 52-year dividend track record. Bears focus on Libre recall, integration debt, and nutrition weakness.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/abt
- Full research API: GET /api/v1/research/ABT/memo
- Coverage universe: /stocks